Drugs / INO 5150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02514213 | Jul 2015 → Dec 2017 | prostate cancer | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-10-22 | Inovio Pharmaceuticals | Results Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150 inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that new data from the company’s recently completed Phase 1b study with INO-5150 demonstrated a slowing of Prostate-Specific Antigen Doubling Time (PSADT) in men with prostate cancer. |
| 2018-05-17 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer inovio.com ↗
Additional analyses show clinically meaningful PSA stabilization post-administration of Inovio’s immunotherapy in patients with no documented disease progression during the study. |
| 2017-09-11 | Inovio Pharmaceuticals | Results Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer inovio.com ↗
The immunology results demonstrate that INO-5150 treatment as a monotherapy generated prostate specific antigen ( PSA) and prostate specific membrane antigen (PSMA) specific T cell responses in peripheral blood in 60% (35/58) of the subjects. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-10-22 | Inovio Pharmaceuticals | Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150 inovio.com ↗ |
| 2018-05-17 | Inovio Pharmaceuticals | Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer inovio.com ↗ |
| 2017-09-11 | Inovio Pharmaceuticals | Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO 5150 | “This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by...” NCT02514213 ↗ |
| Modality | Other / unclassified | “INO-5150 (DNA plasmids encoding prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA))” NCT02514213 ↗ |
| Route | Intramuscular | “delivered intramuscularly” NCT02514213 ↗ |